View More Recent Stories
-
UroGen Pharma (URGN) option IV into data
-
UroGen (URGN) Announces 82.3% Duration of Response at 12 Months in ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
-
UroGen Pharma (URGN) Halted, News Pending
